Amneal Pharmaceuticals (NYSE:AMRX) Shares Gap Down to $5.69

Amneal Pharmaceuticals, Inc. (NYSE:AMRX)’s share price gapped down before the market opened on Thursday . The stock had previously closed at $5.69, but opened at $5.53. Amneal Pharmaceuticals shares last traded at $5.80, with a volume of 1,829 shares trading hands.

Separately, Zacks Investment Research downgraded Amneal Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $7.17.

The stock has a 50 day moving average of $5.26 and a 200-day moving average of $5.41. The company has a market capitalization of $1.73 billion, a P/E ratio of 94.83, a P/E/G ratio of 0.25 and a beta of 1.22. The company has a current ratio of 2.32, a quick ratio of 1.55 and a debt-to-equity ratio of 7.07.

Amneal Pharmaceuticals (NYSE:AMRX) last announced its quarterly earnings data on Sunday, August 8th. The company reported $0.25 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.18 by $0.07. The company had revenue of $535.10 million during the quarter, compared to the consensus estimate of $523.26 million. Amneal Pharmaceuticals had a return on equity of 58.68% and a net margin of 0.45%. The firm’s revenue was up 15.1% on a year-over-year basis. During the same period in the previous year, the company posted $0.13 EPS. As a group, sell-side analysts expect that Amneal Pharmaceuticals, Inc. will post 0.82 EPS for the current fiscal year.

Several large investors have recently made changes to their positions in AMRX. Highland Capital Management LLC bought a new position in shares of Amneal Pharmaceuticals during the 2nd quarter valued at approximately $56,000. Man Group plc purchased a new position in Amneal Pharmaceuticals in the 2nd quarter worth approximately $67,000. Teacher Retirement System of Texas purchased a new position in Amneal Pharmaceuticals in the 1st quarter worth approximately $70,000. Profund Advisors LLC purchased a new position in Amneal Pharmaceuticals in the 1st quarter worth approximately $70,000. Finally, Fox Run Management L.L.C. purchased a new position in Amneal Pharmaceuticals in the 2nd quarter worth approximately $73,000. Institutional investors own 32.91% of the company’s stock.

Amneal Pharmaceuticals Company Profile (NYSE:AMRX)

Amneal Pharmaceuticals, Inc is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals.

See Also: What is a growth and income fund?

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.